These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 18809244

  • 21. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 22. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L.
    Cancer; 2002 Dec 01; 95(11):2373-9. PubMed ID: 12436445
    [Abstract] [Full Text] [Related]

  • 23. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD, Rotunno S, Riedel F, Anders C, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.
    Int J Oncol; 2011 Apr 01; 38(4):1001-12. PubMed ID: 21249316
    [Abstract] [Full Text] [Related]

  • 24. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
    Altuna X, Lopez JP, Yu MA, Arandazi MJ, Harris JP, Wang-Rodriguez J, An Y, Dobrow R, Doherty JK, Ongkeko WM.
    Otol Neurotol; 2011 Jan 01; 32(1):163-70. PubMed ID: 21157293
    [Abstract] [Full Text] [Related]

  • 25. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
    Wang LH, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug 01; 26(8):449-52. PubMed ID: 16383232
    [Abstract] [Full Text] [Related]

  • 26. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 27. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 15; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 28. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 30. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
    Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A.
    Cancer; 2010 Aug 15; 116(16):3892-902. PubMed ID: 20564078
    [Abstract] [Full Text] [Related]

  • 31. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B, Tirnitz-Parker JE, Olynyk JK.
    Gastroenterology; 2008 Sep 15; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [Abstract] [Full Text] [Related]

  • 32. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 15; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 33. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 15; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 34. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D.
    Mol Cancer Res; 2008 May 15; 6(5):706-14. PubMed ID: 18505916
    [Abstract] [Full Text] [Related]

  • 35. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines.
    Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM.
    Melanoma Res; 2006 Apr 15; 16(2):127-35. PubMed ID: 16567968
    [Abstract] [Full Text] [Related]

  • 36. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
    Johnson FM, Yang P, Newman RA, Donato NJ.
    J Exp Ther Oncol; 2004 Dec 15; 4(4):317-25. PubMed ID: 15844661
    [Abstract] [Full Text] [Related]

  • 37. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.
    Haematologica; 2008 May 15; 93(5):653-61. PubMed ID: 18367480
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.
    Clin Cancer Res; 2007 Jun 01; 13(11):3363-9. PubMed ID: 17545544
    [Abstract] [Full Text] [Related]

  • 39. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M.
    Br J Cancer; 2005 May 23; 92(10):1881-91. PubMed ID: 15870711
    [Abstract] [Full Text] [Related]

  • 40. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A.
    Dermatology; 2008 May 23; 216(2):109-17. PubMed ID: 18216472
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.